Patents by Inventor Shuqian Jing

Shuqian Jing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11542336
    Abstract: Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: January 3, 2023
    Assignee: GMAX BIOPHARM LLC
    Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Liangliang Bi, Shuqian Jing
  • Publication number: 20220411520
    Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.
    Type: Application
    Filed: September 16, 2020
    Publication date: December 29, 2022
    Applicant: GMAX BIOPHARM LLC
    Inventors: Hua ZHANG, Xiaofeng WANG, Chenjiang YAO, Cheng ZHANG, Shuqian JING
  • Publication number: 20220265771
    Abstract: Provided is a fusion protein of an ETA antibody and a TGF-? Trap. Also provided is a pharmaceutical composition of the fusion protein of the ETA antibody and the TGF-? Trap. Further provided is a method for treating, preventing, or improving one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension, pulmonary fibrosis, or cardiovascular fibrosis by using the fusion protein of the ETA antibody and the TGF-? Trap.
    Type: Application
    Filed: July 14, 2020
    Publication date: August 25, 2022
    Applicant: GMAX BIOPHARM LLC
    Inventors: Cheng ZHANG, Chenjiang YAO, Hua ZHANG, Xiaofeng WANG, Shuqian JING
  • Publication number: 20210162045
    Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.
    Type: Application
    Filed: November 18, 2020
    Publication date: June 3, 2021
    Applicant: GMAX BIOPHARM LLC
    Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
  • Publication number: 20210163614
    Abstract: Provided herein are an apelin receptor (APJ) antibody and its fusion protein with Elabela. Also provided herein is a pharmaceutical composition of a fusion protein with APJ antibody and Elabela, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension or one or more symptoms of heart failure.
    Type: Application
    Filed: June 13, 2019
    Publication date: June 3, 2021
    Applicant: GMAX BIOPHARM LLC
    Inventors: Cheng Zhang, Lei Sun, Rongzhu Wang, Chenjiang Yao, Xiaofeng Wang, Hua Zhang, Shuqian Jing
  • Publication number: 20210122827
    Abstract: Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.
    Type: Application
    Filed: March 19, 2019
    Publication date: April 29, 2021
    Applicant: GMAX BIOPHARM LLC
    Inventors: Cheng ZHANG, Hua ZHANG, Xiaofeng WANG, Chenjiang YAO, Yan JIANG, Liangliang BI, Shuqian JING
  • Publication number: 20210061904
    Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.
    Type: Application
    Filed: March 19, 2019
    Publication date: March 4, 2021
    Applicant: Gmax Biopharm LLC
    Inventors: Xiaofeng WANG, Hua ZHANG, Chenjiang YAO, Cheng ZHANG, Shuqian JING
  • Patent number: 10869927
    Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: December 22, 2020
    Assignee: GMAX BIOPHARM LLC
    Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
  • Publication number: 20190365894
    Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.
    Type: Application
    Filed: August 12, 2019
    Publication date: December 5, 2019
    Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
  • Patent number: 10485870
    Abstract: Disclosed is a stable pharmaceutical solution formulation of a GLP-1R antibody fusion protein, comprising a therapeutically effective amount of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution formulation is from 5.0 to 8.0. The stable solution formulation of the present invention can be used in the treatment of diabetes, obesity and conditions associated therewith.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: November 26, 2019
    Assignee: Gmax Biopharm LLC.
    Inventors: Cheng Zhang, Hua Zhang, Kesuo Fan, Yong Guo, Shuqian Jing
  • Patent number: 10376581
    Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 13, 2019
    Assignee: Gmax Biopharm LLC.
    Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
  • Publication number: 20190134196
    Abstract: Provided herein are a stable solution formulation of an ETAR antibody, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension or one or more symptoms of cancer of a reproductive organ.
    Type: Application
    Filed: May 27, 2017
    Publication date: May 9, 2019
    Inventors: Cheng Zhang, Kesuo Fan, Yong Guo, Chenjiang Yao, Hua Zhang, Xiaofeng Wang, Shuqian Jing
  • Patent number: 10253103
    Abstract: Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: April 9, 2019
    Assignee: Gmaz Biopharm LLC
    Inventors: Cheng Zhang, Shuqian Jing, Hua Zhang, Xiaofeng Wang, Chenjiang Yao
  • Publication number: 20180346585
    Abstract: Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.
    Type: Application
    Filed: August 13, 2018
    Publication date: December 6, 2018
    Inventors: Cheng Zhang, Shuqian Jing, Hua Zhang, Xiaofeng Wang, Chenjiang Yao
  • Publication number: 20180256714
    Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.
    Type: Application
    Filed: July 22, 2016
    Publication date: September 13, 2018
    Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
  • Patent number: 10059773
    Abstract: Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: August 28, 2018
    Assignee: GMAX BIOPHARM LLC.
    Inventors: Cheng Zhang, Shuqian Jing, Hua Zhang, Xiaofeng Wang, Chenjiang Yao
  • Publication number: 20180000934
    Abstract: Disclosed is a stable pharmaceutical solution formulation of a GLP-1R antibody fusion protein, comprising a therapeutically effective amount of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution formulation is from 5.0 to 8.0. The stable solution formulation of the present invention can be used in the treatment of diabetes, obesity and conditions associated therewith.
    Type: Application
    Filed: February 3, 2016
    Publication date: January 4, 2018
    Inventors: Cheng Zhang, Hua Zhang, Kesuo Fan, Yong Guo, Shuqian Jing
  • Publication number: 20160362498
    Abstract: Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.
    Type: Application
    Filed: August 1, 2014
    Publication date: December 15, 2016
    Inventors: Cheng ZHANG, Shuqian JING, Hua ZHANG, Xiaofeng WANG, Chenjiang YAO
  • Publication number: 20140037635
    Abstract: Novel IL-17 like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof.
    Type: Application
    Filed: June 26, 2013
    Publication date: February 6, 2014
    Applicant: Amgen Inc.
    Inventors: Eugene MEDLOCK, Gary S. ELLIOTT, Shuqian JING, Scott Michael SILBIGER, Hung Q. NGUYEN, Richard YEH
  • Publication number: 20110160438
    Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Application
    Filed: October 28, 2010
    Publication date: June 30, 2011
    Applicant: Amgen Inc.
    Inventors: Eugene Medlock, Richard Yeh, Scott M. Silbiger, Gary S. Elliott, Hung Q. Nguyen, Shuqian Jing